No Data
No Data
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $4
CervoMed Presents Preliminary Findings From Phase 2b RewinD-LB Trial
CervoMed Announces Update On Neflamapimod Development In RewinD-LB Trial; New Capsules Achieved Targeted Plasma Concentrations In 4Q 2024; Data Expected In 1Q 2025
CervoMed to Present at the 8th International Lewy Body Dementia Conference
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
H.C. Wainwright Downgrades CervoMed(CRVO.US) to Hold Rating
74537207 : thank you very much
, I am starting to miss your 'mega' picks a bit ![joy 😂](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f602.png)
6k最后剩多少 : ICON firmly believes it will rebound.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Jaguar8 OP 74537207 : I try to avoid having people focus on the mega picks so they will try to use charts and indicators
Sam19999 : Silent stalker here! Thanks, been learning a lot from you :)
MilaDing : thanks
View more comments...